Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CEO Sells 13,605 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 13,605 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $587,872.05. Following the sale, the chief executive officer now owns 481,918 shares of the company’s stock, valued at $20,823,676.78. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Twist Bioscience Stock Up 1.3 %

Shares of NASDAQ:TWST opened at $43.34 on Friday. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90. The company’s 50-day moving average price is $44.94 and its two-hundred day moving average price is $43.69. The firm has a market cap of $2.52 billion, a P/E ratio of -12.90 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The company had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm’s revenue was up 27.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.01) EPS. As a group, equities analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on TWST shares. JPMorgan Chase & Co. increased their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Evercore ISI increased their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Robert W. Baird increased their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Barclays dropped their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Finally, The Goldman Sachs Group increased their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.63.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the 2nd quarter valued at about $43,000. Blue Trust Inc. boosted its stake in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Twist Bioscience in the 2nd quarter valued at about $61,000. Nisa Investment Advisors LLC boosted its stake in shares of Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after purchasing an additional 546 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.